By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...

Global Anemia Treatment Market size is expected to be worth around USD 19.1 Billion by 2033, from USD 9.7 Billion in 2023, growing at a CAGR of 7.2% Lawrence John Prudour +91 91308 55334 ...

AstraZeneca will obtain the full rights to Roxadustat in China, FibroGen said, adding that it will retain the US and other ...

AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...

The deal comes at a time when the Anglo-Swedish pharma company is facing a string of investigations in the country, ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently ...

Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes the year-end report for 2024. The report is available as an attached document and on the company's ...

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

An unusual swelling in the legs and feet could indicate the onset of kidney damage. When the kidneys struggle to eliminate ...

Dr Ravinder K Gupta, Dr Akhilpreet Kaur Anemia is a serious global public health problem that particularly affects young ...